Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

  • Professor of Medicine, Pharmacology and Toxicology, Biochemistry and Molecular Biology
  • Chief, Division of Medical Oncology and Hematology
  • Director, James Graham Brown Cancer Center
  • Medical Director, Clinical Trials Office, James Graham Brown Cancer Center
  • Associate Director, Translational Research Program, James Graham Brown Cancer Center
  • Brinkley Chair in Lung Cancer Research
UofL James Graham Brown Cancer Center
529 South Jackson Street
Louisville, KY 40202

502-852-2522 - Academic Office
502-562-4370 - Patient Appointments


Clinical Expertise
Metastatic Melanoma; Refractory Solid Tumors; Clinical Trial Testing of Immunotherapeutics; Development of Anti-Metabolites as Targeted Chemotherapies

 

Education and Training

  • Medical School: University of Minnesota
  • Residency: Memorial Sloan-Kettering Cancer Center
  • Fellowship: Cornell University Medical College
  • Ph.D.: University of Minnesota

 

Featured Publications

  • Yalcin A, Solakoglu TH, Ozcan SC, Guzel S, Peker S, Celikler S, Balaban BD, Sevinc E, Gurpinar Y, Chesney JA. 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase-3 is required for transforming growth factor β1-enhanced invasion of Panc1 cells in vitro. Biochem Biophys Res Commun. 2017 Mar 11;484(3):687-693. doi: 10.1016/j.bbrc.2017.01.178. Epub 2017 Feb 1. PubMed PMID: 28161638.
  • Yusuf MB, Amsbaugh MJ, Burton E, Chesney J, Woo S. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. World Neurosurg. 2017 Feb 4. pii: S1878-8750(17)30124-9. doi: 10.1016/j.wneu.2017.01.101. [Epub ahead of print] PubMed PMID: 28179176.
  • O'Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, Chesney J, Clem BF. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res Treat. 2016 Nov;160(1):29-40. Epub 2016 Sep 9. PubMed PMID: 27613609.
  • Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9. PubMed PMID: 27622997.
  • Chesney JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356. Erratum in: Autophagy. 2016;12(2):443. Selliez, Iban [corrected to Seiliez, Iban]. PubMed PMID: 26799652; PubMed Central PMCID: PMC4835977.
  • Chesney JA, Mitchell RA. 25 Years On: A Retrospective on Migration Inhibitory Factor in Tumor Angiogenesis. Mol Med. 2015 Oct 27;21 Suppl 1:S19-24. doi: 10.2119/molmed.2015.00055. Review. PubMed PMID: 26605643; PubMed Central PMCID: PMC4661055.
  • Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26. PubMed PMID: 26014293.
  • Chesney J, Clark J, Lanceta L, Trent JO, Telang S. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor. Oncotarget. 2015 Jul 20;6(20):18001-11. PubMed PMID: 26221874; PubMed Central PMCID: PMC4627231.
  • Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20. PubMed PMID: 25891304.
  • Liu Y, Lu X, Huang L, Wang W, Jiang G, Dean KC, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Darling DS, Postigo A, Dean DC. Erratum: Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nat Commun. 2015 Mar 19;6:6699. doi: 10.1038/ncomms7699. PubMed PMID: 25789446.